Clinical Trial Update: Dapagliflozin Effect in Cognitive Impairment in Stroke Trial [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating dapagliflozin for cognitive impairment in stroke patients is in early or unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Dementia Vascular
• Metabolic Syndrome
• Stroke Ischemic

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Jaime Daniel Mondragon | Conditions: Stroke, Ischemic, Mild Cognitive Impairment | Phase 2, Phase 3 | Status: UNKNOWN